Core Viewpoint - Compass Therapeutics, Inc. (CMPX) has received an upgrade to a Zacks Rank 2 (Buy), indicating a positive outlook based on rising earnings estimates, which significantly influence stock prices [1][3]. Earnings Estimates and Stock Price Movement - The Zacks rating system is effective for individual investors as it focuses on earnings estimate revisions, which are strongly correlated with near-term stock price movements [2][4]. - An increase in earnings estimates typically leads to higher fair value calculations by institutional investors, resulting in stock price movements [4]. Company Performance Indicators - The upgrade for Compass Therapeutics reflects an improvement in the company's underlying business, suggesting that investor sentiment may drive the stock price higher [5]. - The Zacks Consensus Estimate for Compass Therapeutics has increased by 11% over the past three months, although the expected earnings per share for the fiscal year ending December 2024 is projected at -$0.35, representing a year-over-year decline of 6.1% [8]. Zacks Rank System Overview - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with a strong historical performance, particularly for Zacks Rank 1 stocks, which have averaged a +25% annual return since 1988 [7]. - Only the top 20% of Zacks-covered stocks receive a 'Strong Buy' or 'Buy' rating, indicating superior earnings estimate revisions and potential for market-beating returns [9][10].

Core Insights - Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing proprietary antibody-based therapeutics for oncology and other diseases [1][3] - The company will present at the Guggenheim Securities SMID Cap Biotech Conference in New York City on February 5-6, 2025 [1][2] Company Overview - Founded in 2014 and headquartered in Boston, Massachusetts, Compass Therapeutics specializes in the relationship between angiogenesis, the immune system, and tumor growth [3] - The company's pipeline includes novel product candidates targeting critical biological pathways for effective anti-tumor responses, including angiogenesis modulation and immune response induction [3] - Compass plans to advance its product candidates through clinical development as standalone therapies and in combination with proprietary pipeline antibodies [3]

Financial Position - Estimated cash, cash equivalents, and marketable securities were approximately $127 million as of December 31, 2024[6] - The financial data is unaudited and preliminary, subject to completion of financial closing procedures[6] Product Development - The company announced the advancement of a new drug candidate[5]

Core Insights - Compass Therapeutics, Inc. is approaching a significant milestone with the upcoming top-line data readout for its Phase 2/3 study of tovecimig in patients with advanced biliary tract cancer (BTC) expected at the end of Q1 2025 [2][6] - The company has introduced a new drug candidate, CTX-10726, a PD-1 x VEGF-A bispecific antibody, with an IND submission anticipated by the end of 2025 and initial clinical data expected in 2026 [2][6][12] - Compass is progressing with two new Phase 2 biomarker studies, one for tovecimig and another for CTX-471, both expected to start in mid-2025 [2][6] Development Pipeline Updates - Tovecimig (CTX-009) is a DLL4 x VEGF-A bispecific antibody with a top-line data readout scheduled for the end of Q1 2025 in patients with BTC [3][6] - CTX-471 is a CD137 agonist antibody, with a Phase 2 trial initiation expected in mid-2025 targeting tumors expressing NCAM/CD56 [4][6] - CTX-8371 is a PD-1 x PD-L1 bispecific antibody, with the third dosing cohort of its Phase 1 study fully enrolled and preliminary data expected in the second half of 2025 [5][6][12] Financial Position - As of December 31, 2024, Compass Therapeutics reported an estimated $127 million in cash and marketable securities, which is projected to sustain operations into Q1 2027 [9][6]

Core Viewpoint - Compars Therapeutics, Inc. (CMPX) has experienced a significant decline of 23.5% in its stock price over the past four weeks, but it is now in oversold territory, suggesting a potential for a turnaround as analysts expect better earnings than previously predicted [1]. Group 1: Stock Performance and Technical Indicators - CMPX's stock is currently showing signs of being oversold, with a Relative Strength Index (RSI) reading of 28.08, indicating that the heavy selling pressure may be exhausting itself [5]. - The RSI is a momentum oscillator that helps identify whether a stock is oversold, typically when the reading falls below 30 [2]. - The stock's price movements suggest it could soon revert to its previous equilibrium of supply and demand [5]. Group 2: Earnings Estimates and Analyst Sentiment - There has been a strong consensus among sell-side analysts to raise earnings estimates for CMPX, resulting in a 15.4% increase in the consensus EPS estimate over the last 30 days [7]. - An upward trend in earnings estimate revisions is generally associated with price appreciation in the near term [7]. - CMPX holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate trends and EPS surprises, indicating a strong potential for a turnaround [8].

Core Viewpoint - Compass Therapeutics, Inc. (CMPX) has received an upgrade to a Zacks Rank 2 (Buy), indicating a positive trend in earnings estimates which is a significant factor influencing stock prices [1][4]. Earnings Estimates and Revisions - The Zacks rating system is based on the Zacks Consensus Estimate, which reflects EPS estimates from sell-side analysts for the current and following years [2]. - The recent upgrade for Compass Therapeutics reflects an improvement in the company's earnings outlook, potentially leading to increased buying pressure and stock price appreciation [4][6]. - For the fiscal year ending December 2024, Compass Therapeutics is expected to earn -$0.38 per share, representing a -15.2% change from the previous year [9]. Impact of Institutional Investors - Changes in a company's future earnings potential, as indicated by earnings estimate revisions, are strongly correlated with near-term stock price movements, largely due to institutional investors adjusting their valuations based on these estimates [5]. - Institutional investors' actions, driven by earnings estimates, can lead to significant price movements in stocks [5]. Zacks Rank System - The Zacks Rank system categorizes stocks into five groups based on earnings estimates, with a strong historical performance, particularly for Zacks Rank 1 stocks, which have averaged a +25% annual return since 1988 [8]. - The upgrade of Compass Therapeutics to a Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, indicating a strong potential for market-beating returns in the near term [11].

Financial Performance - As of September 30, 2024, Compass Therapeutics reported net losses of $10.5 million for Q3 2024, compared to $10.0 million for Q3 2023, and $34.3 million for the nine months ended September 30, 2024, compared to $29.1 million for the same period in 2023[73]. - The company has an accumulated deficit of $350 million as of September 30, 2024, and expects to continue incurring significant expenses for clinical development over the next few years[73]. - For the three months ended September 30, 2024, total operating expenses increased by $0.3 million, or 2.6%, to $12.239 million compared to $11.926 million for the same period in 2023[85]. - Research and development expenses decreased by $0.2 million, or 2%, to $8.612 million for the three months ended September 30, 2024, compared to $8.831 million for the same period in 2023[86]. - General and administrative expenses increased by $0.5 million, or 17%, to $3.627 million for the three months ended September 30, 2024, primarily due to increased stock compensation costs[87]. - Licensing revenue for the nine months ended September 30, 2024, was $850 thousand, a significant increase from $0 for the same period in 2023, driven by a $1 million milestone payment from Elpiscience[89]. - Research and development expenses increased by $3.6 million, or 14%, to $29.304 million for the nine months ended September 30, 2024, compared to $25.694 million for the same period in 2023[90]. - General and administrative expenses increased by $2.3 million, or 25%, to $11.597 million for the nine months ended September 30, 2024, compared to $9.276 million for the same period in 2023[92]. - Cash used in operating activities for the nine months ended September 30, 2024, was $35.693 million, compared to $28.264 million for the same period in 2023[98]. - Cash provided by financing activities for the nine months ended September 30, 2024, was $17.432 million, significantly higher than $3.093 million for the same period in 2023[102]. - As of September 30, 2024, the company had cash and marketable securities of $135 million, which is expected to fund operations into the first quarter of 2027[94][105]. Clinical Trials and Product Development - CTX-009 is currently in a Phase 2/3 trial in combination with paclitaxel for biliary tract cancer, with 150 patients enrolled and top-line data expected by the end of Q1 2025[62]. - The Phase 2 monotherapy trial of CTX-009 in metastatic colorectal cancer was discontinued after failing to meet response criteria, with an overall response rate of 5% and a disease control rate of 71%[60][61]. - CTX-471, a monoclonal antibody, showed an overall response rate of 27% in advanced melanoma patients during its Phase 1b trial, with five clinical responses reported[67]. - CTX-8371, a bispecific antibody targeting PD-1 and PD-L1, has completed its second cohort in clinical trials with no dose-limiting toxicities observed, and the third cohort is planned for late 2024[71]. - The company plans to initiate a new second-line trial for CTX-009 in metastatic colorectal cancer combined with chemotherapy in mid-2025[61]. - The FDA granted Fast Track Designation to CTX-009 in combination with paclitaxel for the treatment of previously treated metastatic or locally advanced biliary tract cancer[62]. - Compass Therapeutics intends to explore additional indications for CTX-009 based on preclinical models and clinical data, including ovarian, liver, gastric, pancreatic, and renal cell cancers[64]. Funding and Financial Strategy - The company anticipates increased expenses related to ongoing clinical trials and commercialization efforts for its product candidates, necessitating additional funding[96][105]. - The company expects to finance cash needs through equity and debt financings, collaborations, and licensing arrangements[106]. - If additional capital is raised through equity or convertible debt, ownership interest may be materially diluted[106]. - Debt financing may involve restrictive covenants limiting actions such as incurring additional debt or declaring dividends[106]. Internal Controls and Legal Proceedings - The company has evaluated its disclosure controls and procedures as effective as of September 30, 2024[108]. - There were no changes in internal control over financial reporting that materially affected the company during the quarter ended September 30, 2024[109]. - The company is not currently involved in any material legal proceedings, but may face various claims in the ordinary course of business[111].

Financial Performance - The net loss for the quarter ended September 30, 2024, was $10.5 million, or $0.08 per share, compared to a net loss of $10.0 million, or $0.08 per share, for the same period in 2023[8] - The net loss for the nine months ended September 30, 2024, was $34.3 million, or $0.25 per share, compared to a net loss of $29.1 million, or $0.23 per share, for the same period in 2023[8] Research and Development - Research and Development (R&D) expenses for the quarter were $8.6 million, a slight decrease from $8.8 million in the same period in 2023[9] - Clinical costs related to the COMPANION-002 trial increased by $5.2 million, contributing to the overall rise in R&D expenses for the nine months ended September 30, 2024[9] - The Phase 2/3 trial of CTX-009 in patients with biliary tract cancers is fully enrolled, with top-line data readout expected by the end of Q1 2025[1] - A Phase 2 trial of CTX-009 in combination with chemotherapy for DLL4-positive colorectal cancer is being designed, with initiation expected in mid-2025[1] - CTX-471 has shown a correlation between NCAM (CD56) expression and disease control, leading to plans for a Phase 2 trial in mid-2025[1] - The second dosing cohort of the Phase 1 study of CTX-8371 is fully enrolled, with enrollment into the third cohort expected to begin soon[6] Expenses - General and Administrative (G&A) expenses increased to $3.6 million for the quarter, up from $3.1 million in the same period in 2023, primarily due to higher stock compensation expenses[10] Cash and Securities - Cash and marketable securities as of September 30, 2024, totaled $135 million, down from $152 million as of December 31, 2023, providing a cash runway into the first quarter of 2027[11] Liabilities and Equity - Total liabilities increased to $10,753 million from $8,337 million, reflecting a growth of approximately 29.3% year-over-year[21] - Total stockholders' equity decreased to $138,398 million from $148,538 million, indicating a decline of about 6.8%[21] - Total liabilities and stockholders' equity amounted to $149,151 million, down from $156,875 million, representing a decrease of approximately 4.9%[21] - Long-term operating lease obligations are reported at $6,320 million[21]

Financial Performance - As of June 30, 2024, the company reported net losses of $13.1 million for the three months ended June 30, 2024, compared to $11.3 million for the same period in 2023, and $23.9 million for the six months ended June 30, 2024, compared to $19.1 million in 2023[58]. - The net loss for the three months ended June 30, 2024, was $13.1 million, compared to a net loss of $11.3 million for the same period in 2023, reflecting an increase of $1.8 million[69]. - Cash used in operating activities for the six months ended June 30, 2024, was $24.6 million, compared to $22.3 million for the same period in 2023[84]. Revenue and Expenses - Licensing revenue for the three months ended June 30, 2024, was $850 thousand, a significant increase from $0 for the same period in 2023, primarily due to a $1 million milestone payment from Elpiscience[70]. - For the six months ended June 30, 2024, licensing revenue was $850 thousand, with no licensing revenue reported for the same period in 2023[76]. - Research and development expenses increased by $1.0 million, or 9%, for the three months ended June 30, 2024, totaling $11.2 million compared to $10.2 million in the same period in 2023[71]. - Research and development expenses for the six months ended June 30, 2024, increased by $3.8 million, or 23%, totaling $20.7 million compared to $16.9 million in the same period in 2023[77]. - General and administrative expenses rose by $1.6 million, or 52%, for the three months ended June 30, 2024, reaching $4.7 million compared to $3.1 million in the same period in 2023[72]. - General and administrative expenses for the six months ended June 30, 2024, increased by $1.8 million, or 29%, totaling $8.0 million compared to $6.2 million in the same period in 2023[77]. Cash Position and Funding - As of June 30, 2024, the company had $146 million in cash, cash equivalents, and marketable securities, expected to fund operations into Q1 2027[59]. - The company has sufficient cash, cash equivalents, and marketable securities to fund operations and capital expenditures into Q1 2027, based on current plans[89]. - The company expects future funding requirements to increase substantially due to ongoing activities, including clinical trials and regulatory approvals[88]. - The company expects to require additional funding for the clinical development of three programs: CTX-009, CTX-471, and CTX-8371[89]. - The company plans to finance cash needs through equity and debt financings, collaborations, and licensing arrangements, which may dilute ownership interest[90]. Clinical Trials and Development - CTX-009 is currently in two ongoing U.S. clinical trials, with a Phase 2 trial for metastatic colorectal cancer showing a disease control rate of 71% and an overall response rate of 5%[48][49]. - A randomized Phase 2/3 trial for CTX-009 in combination with paclitaxel for biliary tract cancer has fully enrolled 150 patients, with top-line data expected in Q1 2025[49]. - The FDA granted Fast Track Designation to CTX-009 in combination with paclitaxel for the treatment of metastatic or locally advanced biliary tract cancer in April 2024[50]. - CTX-471, a monoclonal antibody, is currently in a Phase 1b clinical trial, with plans for a Phase 2 monotherapy study based on a newly identified biomarker[55][52]. - CTX-8371, a bispecific antibody targeting PD-1 and PD-L1, has completed its first cohort in a clinical trial with no dose-limiting toxicities observed[56]. - The company expects to continue incurring significant expenses for clinical development and regulatory approval for the next several years[58]. - If regulatory approval is received for CTX-009, CTX-471, or CTX-8371, significant commercialization expenses will be incurred related to manufacturing, sales, marketing, and distribution[89]. Legal and Compliance - There were no changes in internal control over financial reporting during the quarter ended June 30, 2024, that materially affected internal controls[93]. - As of the date of the report, the company is not involved in any material legal proceedings, although it may face various claims in the ordinary course of business[95].

[Corporate and Pipeline Highlights](index=1&type=section&id=Corporate%20and%20Pipeline%20Highlights) Compass Therapeutics provides an overview of its Q2 2024 corporate and pipeline achievements [Q2 2024 Key Achievements](index=1&type=section&id=Q2%202024%20Key%20Achievements) Compass Therapeutics announced significant progress across its clinical pipeline in Q2 2024, including trial completions, new study designs, and a strong cash position - Completed enrollment of 150 patients in the COMPANION-002 Phase 2/3 trial of CTX-009 for biliary tract cancers (BTC), with **top-line data anticipated in Q1 2025**[1](index=1&type=chunk) - Based on encouraging preliminary data from the COMPANION-003 trial, the company is evaluating designs for a new Phase 2 study of CTX-009 combined with chemotherapy for **second-line, DLL4-positive colorectal cancer (CRC)**[1](index=1&type=chunk) - Planning a Phase 2 monotherapy trial for CTX-471 in patients with tumors expressing a **newly identified biomarker**, while discontinuing the combination study with KEYTRUDA[2](index=2&type=chunk) - The Phase 1 dose-escalation study of CTX-8371 completed its first dosing cohort without observing **dose-limiting toxicities** and has begun enrolling the second cohort[2](index=2&type=chunk) - Ended the first quarter with **$146 million in cash and marketable securities**, which is expected to provide a **cash runway into the first quarter of 2027**[3](index=3&type=chunk) [CEO Commentary](index=1&type=section&id=CEO%20Commentary) The CEO emphasizes key clinical trial progress for CTX-009 and positive developments across other pipeline programs - The CEO emphasized the achievement of completing enrollment in the **COMPANION-002 Phase 2/3 trial for CTX-009** in patients with Biliary Tract Cancer (BTC)[3](index=3&type=chunk) - An Investigator Sponsored Trial at MD Anderson Cancer Center was approved to evaluate CTX-009 in the **front-line setting for BTC patients**[3](index=3&type=chunk) - Encouraging median overall survival data from the CTX-009 monotherapy trial in advanced Colorectal Cancer (CRC) is driving the design of a new study combining CTX-009 with chemotherapy for **second-line, DLL4-positive patients**[3](index=3&type=chunk) [Development Pipeline Updates](index=1&type=section&id=Development%20Pipeline%20Updates) Detailed updates on the progress of Compass Therapeutics' key clinical development programs [CTX-009 (DLL4 and VEGF-A bispecific antibody)](index=2&type=section&id=CTX-009%20%28DLL4%20and%20VEGF-A%20bispecific%20antibody%29) Enrollment for the Phase 2/3 COMPANION-002 trial in Biliary Tract Cancers (BTC) is complete (n=150), with top-line data expected in Q1 2025. An investigator-sponsored trial for first-line BTC has been approved. Preliminary Phase 2 data in Colorectal Cancer (CRC) showed a 5% Objective Response Rate and 10.2 months median Overall Survival, leading to a new trial design for second-line, DLL4-positive CRC patients instead of continuing the current trial - Completed enrollment (n=150) in the COMPANION-002 Phase 2/3 trial for advanced BTC, with **top-line data expected in Q1 2025**. The drug has also received **FDA Fast Track Designation**[4](index=4&type=chunk) - An Investigator Sponsored Trial (IST) was approved to evaluate CTX-009 in the **first-line BTC setting**, added to the standard regimen of gemcitabine, cisplatin, and durvalumab[4](index=4&type=chunk) Preliminary Phase 2 Data for CTX-009 Monotherapy in CRC | Metric | Result | | :--- | :--- | | Objective Response Rate (ORR) | 5% (2/41 patients) | | Median Progression-Free Survival (PFS) | 3.9 months | | Disease Control Rate (DCR) | 71% (29/41 patients) | | Median Overall Survival (OS) | 10.2 months | - Based on preliminary results from the COMPANION-003 trial, the company will not proceed to Stage 2 and is instead designing a new Phase 2 study for CTX-009 in combination with chemotherapy for **second-line, DLL4-positive CRC patients**[5](index=5&type=chunk) [CTX-471 (CD137 agonist antibody)](index=2&type=section&id=CTX-471%20%28CD137%20agonist%20antibody%29) A potential biomarker for CTX-471 response was identified from a Phase 1b biopsy analysis, prompting the planning of a new Phase 2 monotherapy trial for patients with tumors expressing this biomarker. The combination study with Merck's KEYTRUDA will be discontinued due to an observed suppression of proinflammatory cytokines not seen in monotherapy - The Phase 1b monotherapy study observed **five responses** in patients who had previously received checkpoint inhibitors, including a **complete response in a small cell lung cancer patient** and a **27% ORR in advanced melanoma patients**[6](index=6&type=chunk) - Analysis of biopsy specimens revealed a **potential biomarker of response**, leading to the planning of a Phase 2 monotherapy study in patients whose tumors express this biomarker[6](index=6&type=chunk) - The combination study of CTX-471 with KEYTRUDA (pembrolizumab) will be discontinued due to an **unexpected suppression of proinflammatory cytokines**[7](index=7&type=chunk) [CTX-8371 (PD-1 x PD-L1 bispecific antibody)](index=2&type=section&id=CTX-8371%20%28PD-1%20x%20PD-L1%20bispecific%20antibody%29) The first-in-human Phase 1 dose-escalation study of CTX-8371, a next-generation bispecific checkpoint inhibitor, is progressing well. The first dosing cohort was completed in June 2024 with no dose-limiting toxicities observed, and enrollment for the second cohort has commenced - The first patient in the Phase 1 study was dosed in **April 2024**[7](index=7&type=chunk) - The first dosing cohort was completed with **no dose-limiting toxicities (DLTs) observed**, and the second cohort has been initiated[2](index=2&type=chunk)[7](index=7&type=chunk) [General Updates](index=3&type=section&id=General%20Updates) The company continues its preclinical and discovery work, exploring synergies between VEGF blockade and CD137 agonism to identify new drug candidates. Additionally, two promotions were made to the executive leadership team - Compass continues to explore synergies observed in pre-clinical work between VEGF blockade and CD137 agonism to identify **novel drug candidates**[8](index=8&type=chunk) - Announced two promotions on the executive leadership team: **Jonathan Anderman to SVP, General Counsel & Corporate Secretary**, and **Bing Gong to SVP, Discovery Research**[8](index=8&type=chunk) [Financial Results and Position](index=3&type=section&id=Financial%20Results%20and%20Position) An overview of Compass Therapeutics' financial performance and cash position for Q2 2024 [Financial Performance (Q2 2024)](index=3&type=section&id=Financial%20Performance%20%28Q2%202024%29) Compass Therapeutics reports Q2 2024 net loss and license revenue, with increased losses compared to the prior year Net Loss Overview | Period | Net Loss (in millions) | Net Loss Per Share | | :--- | :--- | :--- | | Q2 2024 | $13.1 | $0.10 | | Q2 2023 | $11.3 | $0.09 | | H1 2024 | $23.9 | $0.17 | | H1 2023 | $19.1 | $0.15 | - The company received a **$1 million milestone payment** related to a Phase 1 trial of CTX-009 in China, which was recognized as **$850 thousand of license revenue**[9](index=9&type=chunk) [R&D and G&A Expenses](index=3&type=section&id=R%26D%20and%20G%26A%20Expenses) Research and Development and General and Administrative expenses increased in Q2 2024 due to clinical costs and CEO departure-related expenses Q2 2024 Expense Breakdown | Expense Category | Q2 2024 (in millions) | Q2 2023 (in millions) | Change Driver | | :--- | :--- | :--- | :--- | | R&D Expenses | $11.2 | $10.2 | +$2.5M in clinical costs for COMPANION-002, offset by -$1.8M in manufacturing expense | | G&A Expenses | $4.7 | $3.1 | Increase due to expenses related to the departure of the CEO | [Cash Position and Runway](index=3&type=section&id=Cash%20Position%20and%20Runway) Compass Therapeutics maintains a strong cash position of $146 million, providing a runway into Q1 2027, despite a slight decrease from year-end 2023 Cash and Marketable Securities | Metric | Amount (in millions) | Date | | :--- | :--- | :--- | | Cash and marketable securities | $146 | June 30, 2024 | | Cash and marketable securities | $152 | Dec 31, 2023 | - The current cash position is expected to provide a **runway into the first quarter of 2027**[12](index=12&type=chunk) - During the first six months of 2024, the company's cash position decreased by **$6 million**, with cash used in operations being partially offset by **$18 million received from stock issuance** via its at-the-market (ATM) offering program[12](index=12&type=chunk) [Company and Product Information](index=3&type=section&id=Company%20and%20Product%20Information) Key details about Compass Therapeutics and its lead product candidate, CTX-009 [About CTX-009](index=3&type=section&id=About%20CTX-009) CTX-009 is a bispecific antibody targeting DLL4 and VEGF-A, demonstrating robust anti-tumor activity across various solid tumors - CTX-009 is a bispecific antibody that blocks both **DLL4 and VEGF-A signaling pathways**, which are critical to angiogenesis and tumor vascularization[13](index=13&type=chunk) - Preclinical and early clinical data suggest **robust anti-tumor activity** across several solid tumors, including colorectal, gastric, cholangiocarcinoma, pancreatic, and non-small cell lung cancer[13](index=13&type=chunk) [About Compass Therapeutics](index=3&type=section&id=About%20Compass%20Therapeutics) Compass Therapeutics is a clinical-stage biopharmaceutical company focused on developing proprietary antibody-based cancer therapies - Compass Therapeutics is a **clinical-stage, oncology-focused biopharmaceutical company** developing proprietary antibody-based therapeutics[14](index=14&type=chunk) - The company's scientific focus is on the relationship between **angiogenesis, the immune system, and tumor growth**[14](index=14&type=chunk) - The pipeline is designed to target multiple biological pathways for an effective anti-tumor response, including **modulation of microvasculature and induction of potent immune responses**[14](index=14&type=chunk)